<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="90568">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01713153</url>
  </required_header>
  <id_info>
    <org_study_id>2.4.9</org_study_id>
    <nct_id>NCT01713153</nct_id>
  </id_info>
  <brief_title>Comparing Misoprostol and Oxytocin in Uniject for Postpartum Hemorrhage (PPH) Prevention in Senegal</brief_title>
  <official_title>Preventing Postpartum Hemorrhage: Examining Two Strategies for PPH Prevention in Communities: Misoprostol and Oxytocin Uniject in Senegal</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gynuity Health Projects</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Child Fund International</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gynuity Health Projects</source>
  <oversight_info>
    <authority>Senegal: Ministry of Health and Prevention</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a large, community-based, cluster-randomized trial to compare routine prophylactic
      use of 600 mcg oral misoprostol and 10 IU oxytocin delivered by UnijectTM intramuscularly
      during the third stage of labor
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will assess the programmatic implications (including feasibility, acceptability,
      risks and benefits) at the community level of the introduction of misoprostol and/or
      oxytocin in UnijectTM for the prevention of PPH and will help to identify the appropriate
      niche for both drugs.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">January 2014</completion_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Mean change in hemoglobin</measure>
    <time_frame>during 3rd trimester and 1-3 days postpartum</time_frame>
    <safety_issue>No</safety_issue>
    <description>To establish the comparable effectiveness of two technologies, individual pre- and post-delivery Hb measures will be taken to calculate change in Hb. This will be done using a Hemocue Hemoglobin machine + cuvette (HemoCue, Angelholm, Sweden). The Hemocue is a simple means of collecting Hb measures at the community-level where traditional laboratory techniques are not feasible</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence and management of side effects</measure>
    <time_frame>1 hour postpartum</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>nausea, vomiting, diarrhea, shivering, fever</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>correct timing of drug administration</measure>
    <time_frame>collected immediately following birth, verified 1-3 days postpartum</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>administration of the drug after the birth of the baby and verifying no twin, before the expulsion of the placenta</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in hemoglobin â‰¥ 2 g/dL</measure>
    <time_frame>during third trimester and 1-3 days postpartum</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>additional interventions</measure>
    <time_frame>during birth</time_frame>
    <safety_issue>No</safety_issue>
    <description>use of additional uterotonics, manual removal of placental fragments, etc</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>referrals</measure>
    <time_frame>0-3 days postpartum</time_frame>
    <safety_issue>No</safety_issue>
    <description>referral requested, transfers carried out, reasons for incomplete referrals/transfers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>acceptability</measure>
    <time_frame>1-3 days postpartum</time_frame>
    <safety_issue>No</safety_issue>
    <description>acceptability according to woman of study medication, care received, side effects experienced</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">682</enrollment>
  <condition>Postpartum Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Misoprostol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>600 mcg oral misoprostol administered during the third stage of labor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UnijectTM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 IU oxytocin delivered IM with UnijectTM during he third stage of labor</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol</intervention_name>
    <description>600 mcg misoprostol oral</description>
    <arm_group_label>Misoprostol</arm_group_label>
    <other_name>Cytotec</other_name>
    <other_name>Misoclear</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>UnijectTM</intervention_name>
    <description>10 IU oxytocin delivered intramuscularly with UnijectTM</description>
    <arm_group_label>UnijectTM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  women delivering in community health centers (case de sante) with a trained study
             provider (matrone) who are able to provide informed consent

        Exclusion Criteria:

          -  women with known contraindications to prostaglandins
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Health huts in the district of Thiadiaye and Kolda</name>
      <address>
        <city>Thiadiay and Kolda</city>
        <state>Thiadiaye and Kolda</state>
        <country>Senegal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mamadou Diagne</last_name>
      <phone>+221776342918</phone>
      <email>mdiagne@senegal.childfund.org</email>
    </contact>
    <contact_backup>
      <last_name>Maimouna Sow</last_name>
      <phone>+221776357924</phone>
      <email>msow@senegal.childfund.org</email>
    </contact_backup>
    <investigator>
      <last_name>Bocar Daff</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mamadou Diagne</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ayisha Diop</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jennifer Blum</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Senegal</country>
  </location_countries>
  <link>
    <url>http://gynuity.org/programs/more/prevention-of-postpartum-prevention</url>
    <description>Related Info</description>
  </link>
  <verification_date>October 2012</verification_date>
  <lastchanged_date>October 22, 2012</lastchanged_date>
  <firstreceived_date>October 22, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>postpartum hemorrhage</keyword>
  <keyword>prevention</keyword>
  <keyword>misoprostol</keyword>
  <keyword>Uniject</keyword>
  <keyword>oxytocin</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Postpartum Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Oxytocin</mesh_term>
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
